SCHEMBL5479537

SCHEMBL5479537

CC(C)(C)OC(=O)NC(S)(C=O)CC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.41
AKT1 P31749 3/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39
MAPK10 P53779 1/20 0.37
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
CTSK P43235 4/20 0.36
CTSS P25774 4/20 0.36
ACE P12821 1/20 0.36
POLB P06746 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5485091 1.00 ATM (0.41) ATMAKT1CA12CA1CA7
SCHEMBL7849694 0.74 MAPT (0.39) ATMAKT1CA12CA1CA7
SCHEMBL3375626 0.72 MAPT (0.42) ATMAKT1CA12CA1CA7
SCHEMBL27791882 0.72 KMT2A (0.45) ATMAKT1CA12CA1CA7
SCHEMBL3009386 0.70 CYP1A2 (0.43) ATMAKT1CA12CA1CA7
SCHEMBL29770797 0.70 CA12 (0.44) ATMAKT1CA12CA1CA7
SCHEMBL27437344 0.70 AKT1 (0.43) ATMAKT1CA12CA1CA7
SCHEMBL3592587 0.70 CA12 (0.48) ATMAKT1CA12CA1CA7
SCHEMBL3592585 0.70 CA12 (0.48) ATMAKT1CA12CA1CA7
SCHEMBL2067964 0.70 IDO1 (0.43) ATMAKT1CA12CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015439-B1 PRENYL TRANSFERASE INHIBITORS SOD CONSEILS RECH APPLIC (FR) 2007-04-11 EP disclosed
EP-1676855-A2 Prenyl transferase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. (S.C.R.A.S.) (FR) 2006-07-05 EP disclosed
US-6313109-B2 ANTIPROLIFERATIVE AGENTS; TREATING TUMORS, RESTENOSIS SOCIETE DE CONSEILS DE RECHERCHES D'APPLICATIONS SCIENTIFIQUES, SAS (FR) 2001-11-06 US disclosed
US-20010000344-A1 Prenyl transferase inhibitors BIOMEASURE INCORPORATED 2001-04-19 US disclosed
US-6180619-B1 TREATING TUMORS OR RESTENOSIS BIOMEASURE, INCORPORATED 2001-01-30 US disclosed
US-5767274-A TREATING TUMORS OR RESTENOSIS BIOMEASURE, INCORPORATED (US) 1998-06-16 US disclosed
EP-0784473-A4 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO INC (US) 1997-12-17 EP disclosed
EP-0784473-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO. INC. (US) 1997-07-23 EP disclosed
WO-1996009820-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-04-04 WO disclosed
US-5504115-A MERCAPTO-GROUP CONTAINING DIPEPTIDES; ANTICARCINOGENIC AGENTS MERCK & CO., INC. (US) 1996-04-02 US disclosed
US-5491164-A DOPEPTIDE ANALOGS MERCK & CO., INC. (US) 1996-02-13 US disclosed
EP-0664789-A4 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE. 1995-09-06 EP disclosed
EP-0664789-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE Merck & Co., Inc. (a New Jersey corp.) (US) 1995-08-02 EP disclosed
US-5352705-A Dipeptide-based amide compounds; anticarcinogenic agents MERCK & CO., INC. (US) 1994-10-04 US disclosed
WO-1994000419-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1994-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010000344-A1 Prenyl transferase inhibitors FNTA, FNTB, RCE1 ATM 3565/4885AKT1 260/4885CA12 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.